Euroopa Liit - eesti - EMA (European Medicines Agency)

sanofi winthrop industrie - dupilumab - dermatitis, atopic; prurigo; esophageal diseases; asthma; sinusitis - dermatiidi ained, välja arvatud kortikosteroidid - atopic dermatitisadults and adolescentsdupixent is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. children 6 months to 11 years of agedupixent is indicated for the treatment of severe atopic dermatitis in children 6 months to 11 years old who are candidates for systemic therapy. asthmaadults and adolescentsdupixent is indicated in adults and adolescents 12 years and older as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), see section 5. 1, who are inadequately controlled with high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. children 6 to 11 years of agedupixent is indicated in children 6 to 11 years old as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), who are inadequately controlled with medium to high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. chronic rhinosinusitis with nasal polyposis (crswnp)dupixent is indicated as an add-on therapy with intranasal corticosteroids for the treatment of adults with severe crswnp for whom therapy with systemic corticosteroids and/or surgery do not provide adequate disease control. prurigo nodularis (pn)dupixent is indicated for the treatment of adults with moderate-to-severe prurigo nodularis (pn) who are candidates for systemic therapy. eosinophilic esophagitis (eoe)dupixent is indicated for the treatment of eosinophilic esophagitis in adults and adolescents 12 years and older, weighing at least 40 kg, who are inadequately controlled by, are intolerant to, or who are not candidates for conventional medicinal therapy.

Eesti - eesti - Ravimiamet

glaxosmithkline eesti oÜ - montelukast - õhukese polümeerikattega tablett - 10mg 7tk; 10mg 10tk; 10mg 90tk; 10mg 98tk; 10mg 30tk; 10mg 28tk; 10mg 50tk; 10mg 56tk; 10mg 100tk

Eesti - eesti - Ravimiamet

accord healthcare b.v. - montelukast - õhukese polümeerikattega tablett - 10mg 20tk; 10mg 50tk; 10mg 200tk; 10mg 84tk; 10mg 7tk; 10mg 30tk; 10mg 28tk; 10mg 98tk; 10mg 10tk; 10mg 14tk

Eesti - eesti - Ravimiamet

glaxosmithkline eesti oÜ - montelukast - närimistablett - 5mg 7tk; 5mg 56tk; 5mg 20tk; 5mg 10tk; 5mg 50tk; 5mg 28tk; 5mg 90tk; 5mg 100tk; 5mg 30tk

Eesti - eesti - Ravimiamet

glaxosmithkline eesti oÜ - montelukast - närimistablett - 4mg 90tk; 4mg 56tk; 4mg 10tk; 4mg 28tk; 4mg 7tk; 4mg 98tk; 4mg 50tk

Eesti - eesti - Ravimiamet

roche eesti osaühing - alfadornaas - nebuliseeritav lahus - 1mg 1ml 2.5ml 6tk

Eesti - eesti - Ravimiamet

orion corporation - montelukast - tablett - 10mg 98tk; 10mg 28tk; 10mg 56tk

Eesti - eesti - Ravimiamet

ferring gmbh - budesoniid - toimeainet prolongeeritult vabastav tablett - 9mg 20tk; 9mg 30tk; 9mg 80tk; 9mg 10tk; 9mg 50tk

Eesti - eesti - Ravimiamet

agepha pharma s.r.o. - atsikloviir - silmasalv - 30mg 1g 4.5g 1tk

Eesti - eesti - Ravimiamet

sandoz pharmaceuticals d.d. - formoterool - inhalatsioonipulber kõvakapslis - 12mcg 30tk